The clinical efficacy of lipid-lowering therapy for patients with renal atherosclerosis hypertension
PANG Guang-jie
LI Tong
YUAN Tian-yang
LIU Yang
TIAN Wei-dong
LI Jun
JIANG Xue-ting
ZHANG Jing
Abstract：Objective To observe the clinical efficacy of lipid-lowering therapy for patients with renal atherosclerosis hypertension.Methods We selected 28 patients diagnosed as renal atherosclerosis hypertension by renal artery ultrasound. All patients were given antihypertensive drugs and atorvastatin for 1 year. We observed blood lipids, inflammatory factors, liver function, creatine kinase, renal artery peak systolic velocity (PSV) and renal artery and abdominal aortic peak systolic velocity ratio (RAR).Results The levels of total cholesterol (TC), triglyceride (TG), low density lipoprotein (LDL-C), oxidized low density lipoprotein (OX-LDL) were significantly lower with the extension of treatment time, the difference was statistically significant (P<0.05). The LDL-C reduction was positively correlated with PSV, and RAR change (r=0.288, and 0.061,P<0.05). The OX-LDL reduction was positively correlated with PSV, and RAR change (r=0.250, and 0.121,P<0.05). After the lipid-lowering therapy with atorvastatin, the levels of inflammatory factors (MMP-2, MMP-9 and CRP) were decreased obviously, the difference was statistically significant (P<0.05). The changes of ALT, AST and CK were not statistically different (P>0.05) after the lipid-lowering therapy.Conclusion The lipid-lowering therapy can control atherosclerotic renal artery stenosis, and shows good security.
Keywords：Renal atherosclerosisRenovascular hypertensionStatinsInflammatory factor
Publication Date：2016-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：3( 724-726 )